1
|
Given SH, Reid Ponte P, Lally K, Chua IS. Interdisciplinary Pain Board for Managing Patients with Palliative Care Needs and Substance Use Disorder: A Pilot Study. J Palliat Med 2024. [PMID: 38899507 DOI: 10.1089/jpm.2024.0025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/21/2024] Open
Abstract
Context: Patients with cancer-related pain and concurrent substance use disorder (SUD) present a unique set of challenges for palliative care clinicians. A structured forum for interdisciplinary collaboration is needed to effectively manage this complex population. Objectives: Describe the feasibility and acceptability of a palliative care Complex Pain Board (CPB), an interdisciplinary team meeting to provide concrete care recommendations for patients with cancer-related pain and concurrent SUD and/or psychosocial complexity. Methods: We conducted a retrospective analysis of cases presented at CPB between May 2021 and June 2022 and a cross-sectional analysis of CBP participant surveys. Results: Among 28 cases included for analysis, gastrointestinal cancers (n = 7, 25.9%) and multiple myeloma (n = 5, 18.5%) were the most frequent cancer diagnoses. Primary reasons for referral were SUD (n = 22, 78.6%) and provider/team distress (n = 13, 46.4%). The most frequent recommendations made at CBP were encouraging interdisciplinary collaboration (n = 18, 64.3%), maintaining healthy boundaries (n = 15, 53.6%), and SUD management (n = 13, 46.4%). Of 14 scheduled meetings, most meetings involved the presentation of ≥1 cases (n = 12, 86%). Among 40 CBP participant surveys, most attendees (n = 38, 95%) were likely or highly likely to continue to attend. Conclusion: CPB is a feasible and acceptable intervention that allows for palliative care clinicians to collaborate and receive interdisciplinary team feedback and peer support on the management of patients with cancer-related pain and concurrent SUD and/or psychosocial complexity in the ambulatory care setting. Key Message: A regular, interdisciplinary team meeting (CPB) is a feasible and acceptable intervention to help palliative care clinicians manage challenging cases involving patients with cancer and concurrent SUD and/or psychosocial complexity.
Collapse
Affiliation(s)
- Sarah Hauke Given
- Division of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
- Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA
| | - Patricia Reid Ponte
- Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA
| | - Kate Lally
- Division of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
- Division of Palliative Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | - Isaac S Chua
- Division of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
- Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
2
|
Taylor A, Davies A. The role of specialist palliative care in individuals "living beyond cancer": a narrative review of the literature. Support Care Cancer 2024; 32:414. [PMID: 38842641 PMCID: PMC11156725 DOI: 10.1007/s00520-024-08598-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2024] [Accepted: 05/22/2024] [Indexed: 06/07/2024]
Abstract
PURPOSE Many patients living beyond cancer experience significant unmet needs, although few of these patients are currently reviewed by specialist palliative care teams (SPCTs). The aim of this narrative review was to explore the current and potential role of SPCTs in this cohort of patients. METHODS A search strategy was developed for Medline, and adapted for Embase, CINAHL, and PsycInfo. Additionally, websites of leading oncology, cancer survivorship, and specialist palliative care organisations were examined. The focus of the search was on individuals living beyond cancer rather than other groups of cancer survivors. RESULTS 111 articles were retrieved from the search for full text review, and 101 other sources of information were identified after hand searching the reference lists of the full text articles, and the aforesaid websites. The themes of the review encompass the definition of palliative care/specialist palliative care, current models of specialist palliative care, core activities of SPCTs, relevant expertise of SPCTs, and potential barriers to change in relation to extending their support and expertise to individuals living beyond cancer. The review identified a paucity of evidence to support the role of SPCTs in the management of patients living beyond cancer. CONCLUSIONS Individuals living beyond cancer have many unmet needs, and specific services are required to manage these problems. Currently, there is limited evidence to support the role of specialist palliative care teams in the management of this cohort of people, and several potential barriers to greater involvement, including limited resources, and lack of relevant expertise.
Collapse
Affiliation(s)
- Amy Taylor
- Research Fellow / Specialty Trainee in Palliative Medicine, Trinity College Dublin and Our Lady's Hospice, Dublin, Ireland
| | - Andrew Davies
- Palliative Medicine, Trinity College Dublin and University College Dublin and Our Lady's Hospice, Dublin, Ireland.
- Education & Research Centre, Our Lady's Hospice Dublin, Harold's Cross, Dublin, D6W RY72, Ireland.
| |
Collapse
|
3
|
Shanholtz G, Vergara FH, Amba KT, Ramos MD. Bowel Management Protocol: Impact on Care Transitions of Oncology Patients. Prof Case Manag 2024; 29:22-29. [PMID: 37983778 DOI: 10.1097/ncm.0000000000000669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2023]
Abstract
PURPOSE OF STUDY The project aimed to determine the impact of a standardized bowel regimen protocol for patients receiving opioids on the rate of stool softener prescription, occurrence of bowel movements of oncology patients, and improving the length of stay (LOS). PRIMARY PRACTICE OF SETTING Oncology unit in a community hospital. METHODOLOGY AND SAMPLE A posttest design was utilized, and a prospective medical record review of patients was completed after 8 weeks of the pilot study. The study sample (N = 164) included oncology patients admitted to a community hospital in the Southeast. The χ2 test was used to determine the impact of implementing a bowel panel order on the rate of stool softener prescriptions, the occurrence of bowel movements, and the LOS. RESULTS Only 43% (n = 40) of the patients from the comparison group were ordered laxatives, and more patients from the intervention group (68%; n = 49) received the bowel regimen protocol, whereas 26% (n = 19) of the patients used a laxative or stool softener using providers' preference and demonstrated statistical significance (p = .001). In the intervention group, 93% of the patients (n = 67) reported having bowel movements compared with the comparison group, whereas only 32% (n = 32) demonstrated statistical significance (p = .001). The average LOS in the intervention group is less than 9 days compared with the comparison group, which was at 9 days (p = .001). IMPLICATIONS TO CASE MANAGEMENT PRACTICE Case managers play a critical role in coordinating care, improving transitions of care, and reducing LOS. Case managers can have a significant impact by monitoring and reminding nurses to report the gastrointestinal movements of oncology patients and then escalate opioid-induced constipation with the providers immediately. Case managers can facilitate the implementation of bowel regimen protocols, which may reduce hospitalizations and enhance patient outcomes, by taking this action.
Collapse
Affiliation(s)
- Gayle Shanholtz
- Gayle Shanholtz, DNP, RN, PMH-BC, NEA-BC, was a doctorate student for this project and was a nurse educator for neurology and oncology specializing in performance improvement, education, and outcome reviews to improve patient care. The school of nursing and southern hospital-site IRBs approved this project. Currently, she is the chief of acute care nursing services at the Martinsburg Veterans Affairs Medical Center in West Virginia
- Franz Henryk Vergara, PhD, DNP, RN, CENP, CCM, ONC, was the doctoral capstone chairman and he was the supervising faculty of Dr. Shanholtz. Currently, Dr. Vergara is a principal consultant at Nurse Atbp LLC, Columbia, Maryland
- Katheryne Tifuh Amba, PhD, DNP, RN, ACNP-BC, CCRN, is nurse scientist at SSM Health Cardinal Glennon Children's Hospital, St Louis, Missouri
- Mary Dioise Ramos, PhD, RN, is associate professor at WellStar College of Health and Human Services, Kennesaw State University, Kennesaw, Georgia
| | - Franz Henryk Vergara
- Gayle Shanholtz, DNP, RN, PMH-BC, NEA-BC, was a doctorate student for this project and was a nurse educator for neurology and oncology specializing in performance improvement, education, and outcome reviews to improve patient care. The school of nursing and southern hospital-site IRBs approved this project. Currently, she is the chief of acute care nursing services at the Martinsburg Veterans Affairs Medical Center in West Virginia
- Franz Henryk Vergara, PhD, DNP, RN, CENP, CCM, ONC, was the doctoral capstone chairman and he was the supervising faculty of Dr. Shanholtz. Currently, Dr. Vergara is a principal consultant at Nurse Atbp LLC, Columbia, Maryland
- Katheryne Tifuh Amba, PhD, DNP, RN, ACNP-BC, CCRN, is nurse scientist at SSM Health Cardinal Glennon Children's Hospital, St Louis, Missouri
- Mary Dioise Ramos, PhD, RN, is associate professor at WellStar College of Health and Human Services, Kennesaw State University, Kennesaw, Georgia
| | - Katheryne Tifuh Amba
- Gayle Shanholtz, DNP, RN, PMH-BC, NEA-BC, was a doctorate student for this project and was a nurse educator for neurology and oncology specializing in performance improvement, education, and outcome reviews to improve patient care. The school of nursing and southern hospital-site IRBs approved this project. Currently, she is the chief of acute care nursing services at the Martinsburg Veterans Affairs Medical Center in West Virginia
- Franz Henryk Vergara, PhD, DNP, RN, CENP, CCM, ONC, was the doctoral capstone chairman and he was the supervising faculty of Dr. Shanholtz. Currently, Dr. Vergara is a principal consultant at Nurse Atbp LLC, Columbia, Maryland
- Katheryne Tifuh Amba, PhD, DNP, RN, ACNP-BC, CCRN, is nurse scientist at SSM Health Cardinal Glennon Children's Hospital, St Louis, Missouri
- Mary Dioise Ramos, PhD, RN, is associate professor at WellStar College of Health and Human Services, Kennesaw State University, Kennesaw, Georgia
| | - Mary Dioise Ramos
- Gayle Shanholtz, DNP, RN, PMH-BC, NEA-BC, was a doctorate student for this project and was a nurse educator for neurology and oncology specializing in performance improvement, education, and outcome reviews to improve patient care. The school of nursing and southern hospital-site IRBs approved this project. Currently, she is the chief of acute care nursing services at the Martinsburg Veterans Affairs Medical Center in West Virginia
- Franz Henryk Vergara, PhD, DNP, RN, CENP, CCM, ONC, was the doctoral capstone chairman and he was the supervising faculty of Dr. Shanholtz. Currently, Dr. Vergara is a principal consultant at Nurse Atbp LLC, Columbia, Maryland
- Katheryne Tifuh Amba, PhD, DNP, RN, ACNP-BC, CCRN, is nurse scientist at SSM Health Cardinal Glennon Children's Hospital, St Louis, Missouri
- Mary Dioise Ramos, PhD, RN, is associate professor at WellStar College of Health and Human Services, Kennesaw State University, Kennesaw, Georgia
| |
Collapse
|
4
|
O'Regan A, Fish LJ, Makarushka C, Somers T, Fitzgerald Jones K, Merlin JS, Dinan M, Oeffinger K, Check D. Managing Chronic Pain in Cancer Survivorship: Communication Challenges and Opportunities as Described by Cancer Survivors. Am J Hosp Palliat Care 2024; 41:78-86. [PMID: 36927121 DOI: 10.1177/10499091231164634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023] Open
Abstract
OBJECTIVES Many cancer survivors experience chronic pain after completing curative-intent treatment. Based on available data, chronic pain may be undertreated in this context; however, little is known about cancer survivors' experiences with clinical management of chronic pain. The purpose of this study was to better understand cancer survivors' pain management experiences after curative-intent treatment. METHODS We conducted 13 semi-structured interviews with a convenience sample of cancer survivors who had completed treatment for stage I-III breast, head/neck, lung or colorectal cancer. We used a thematic approach to qualitative data analysis. RESULTS Participants described that chronic pain often goes unrecognized by their providers, potentially due to limitations in how pain is assessed clinically and the tendency of both cancer survivors and providers to minimize or invalidate the pain experience. To improve communication, participants suggested that providers ask more open-ended questions about their pain, help them to establish functional goals, and provide patients with options for pain management. SIGNIFICANCE OF RESULTS This study demonstrates the importance of provider-initiated communication around pain management for cancer survivors to make them feel more supported in their care. Communication and shared decision-making interventions may improve cancer survivor-provider communication around chronic pain management, addressing an important gap in survivorship care.
Collapse
Affiliation(s)
- Amy O'Regan
- Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA
| | - Laura J Fish
- Duke Cancer Institute, Duke University Health System, Durham, NC, USA
- Department of Family Medicine and Community Health, Duke School of Medicine Durham, NC, USA
| | - Christina Makarushka
- Duke Cancer Institute, Duke University Health System, Durham, NC, USA
- Duke Global Health Institute, Durham, NC, USA
| | - Tamara Somers
- Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
| | - Katie Fitzgerald Jones
- Veterans Affairs Boston Healthcare System, Boston, MA, USA
- Harvard Medical School, Harvard University, Cambridge, MA, USA
| | - Jessica S Merlin
- Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Michaela Dinan
- Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA
- Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, CT, USA
| | - Kevin Oeffinger
- Duke Cancer Institute, Duke University Health System, Durham, NC, USA
- Department of Medicine, Duke University School of Medicine, Durham, NC, USA
| | - Devon Check
- Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA
- Duke Cancer Institute, Duke University Health System, Durham, NC, USA
| |
Collapse
|
5
|
Jones KF, Magee LW, Fu MR, Bernacki R, Bulls H, Merlin J, McTernan M. The Contribution of Cancer-Specific Psychosocial Factors to the Pain Experience in Cancer Survivors. J Hosp Palliat Nurs 2023; 25:E85-E93. [PMID: 37402212 PMCID: PMC10524730 DOI: 10.1097/njh.0000000000000965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/06/2023]
Abstract
Palliative care teams are increasingly called up to manage chronic pain in cancer survivors. Chronic pain is common in cancer survivors and is heavily influenced by biopsychosocial factors. This study aimed to determine the relative contribution of unique cancer-specific psychosocial factors, pain catastrophizing, and multisite pain to the pain experience in 41 cancer survivors who completed curative cancer treatment. To test the research hypotheses, a series of nested linear regression models were used with likelihood ratio testing to test the individual and collective contribution of cancer-specific psychosocial factors (fear of cancer recurrence, cancer distress, cancer-related trauma), pain catastrophizing, and the number of pain sites on the pain experience. The results indicate pain catastrophizing and multisite pain explained a significant degree of variance in pain interference scores ( P < .001) and pain severity ( P = .005). Cancer-specific psychosocial factors did not significantly predict variability in pain interference ( P = .313) or pain severity ( P = .668) over and above pain catastrophizing and the number of sites of pain. In summary, pain catastrophizing and multisite pain contribute to the chronic cancer-related pain experienced by cancer survivors. Palliative care nurses are well positioned to improve chronic pain among cancer survivors by assessing and treating pain catastrophizing and multisite pain.
Collapse
Affiliation(s)
- Katie Fitzgerald Jones
- Boston College, William F. Connell School of Nursing and Massachusetts General Hospital Center for Aging and Serious Illness
| | | | - Mei R. Fu
- Rutgers University School of Nursing-Camden
| | | | | | | | | |
Collapse
|
6
|
Jones KF, Fu MR, Wood Magee L, Merlin J, Check DK, McTernan M, Bernacki R, Bulls HW. "It Is So Easy For Them to Dismiss": A Phenomenological Study of Cancer Survivors With Chronic Cancer-Related Pain. J Palliat Med 2023; 26:1090-1099. [PMID: 36944115 PMCID: PMC10440651 DOI: 10.1089/jpm.2022.0538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/13/2023] [Indexed: 03/23/2023] Open
Abstract
Background: For many cancer survivors post-cure, chronic pain is a devastating complication of cancer treatment. The prevalence of chronic pain among cancer survivors is double that of the general population. However, little is known about the pain experience of cancer survivors who may have a different perspective than people with advanced cancer or people with noncancer pain. Objective: To understand the lived experience of chronic cancer-related pain in cancer survivors. Methods: We used a qualitative design with a descriptive phenomenological method to conduct in-depth interviews of 13 cancer survivors residing in the United States who completed curative cancer therapy, were at least three months from treatment, and experienced pain attributable to cancer. Data collection was focused on the lived experience and management of chronic cancer-related pain and a deep understanding of how the experience of chronic cancer-related pain shapes pain management choices. Results: The participants had a variety of primary cancer types and cancer pain syndromes. Three essential themes epitomized the experience of living with chronic cancer-related pain: invisible suffering at the cost of survival, an opioid paradox, and a lack of answers on what to expect and what might help. Conclusion and Implications: The results highlight an opportunity for pain self-management, education, and psychosocial interventions to optimize pain in cancer. Participants' experiences identify several opportunities to improve chronic cancer-related pain. Future efforts should prioritize access to multimodal pain treatments, high-quality communication, and expand clinicians' knowledge and skills to manage chronic pain.
Collapse
Affiliation(s)
| | - Mei R. Fu
- School of Nursing–Camden, Rutgers University, Camden, New Jersey, USA
| | - Lisa Wood Magee
- William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA
| | - Jessica Merlin
- Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Devon K. Check
- Population Health Sciences, Duke Cancer Institute, Durham, North Carolina, USA
| | - Melissa McTernan
- William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA
| | - Rachelle Bernacki
- Division of Psychosocial Oncology and Palliative Care, Dana Faber-Cancer Institute, Boston, Massachusetts, USA
| | - Hailey Waddell Bulls
- Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| |
Collapse
|
7
|
Check DK, Jones KF, Fish LJ, Dinan MA, Dunbar TK, Farley S, Ma J, Merlin JS, O'Regan A, Oeffinger KC. Clinician Perspectives on Managing Chronic Pain After Curative-Intent Cancer Treatment. JCO Oncol Pract 2023; 19:e484-e491. [PMID: 36595729 PMCID: PMC10530392 DOI: 10.1200/op.22.00410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 08/19/2022] [Accepted: 11/04/2022] [Indexed: 01/04/2023] Open
Abstract
PURPOSE Among cancer survivors who have completed curative-intent treatment, the high prevalence and adverse consequences of chronic pain are well documented. Yet, research on clinicians' experiences with and perspectives on managing chronic pain among cancer survivors is critically lacking. METHODS We conducted semistructured interviews with 17 clinicians (six oncology, three palliative care, and eight primary care) affiliated with an academic medical center. Interview questions addressed clinicians' experiences with and perspectives on managing chronic pain (with or without opioid therapy) during the transition from active treatment to survivorship. A multidisciplinary team conducted content analysis of interview transcripts to identify and refine themes related to current practices and challenges in managing chronic pain in this context. RESULTS Overall, clinicians perceived chronic pain to be relatively uncommon among cancer survivors. Identified challenges included a lack of clarity about which clinician (or clinicians) are best positioned to manage chronic pain among cancer survivors, and (relatedly) complexities introduced by long-term opioid management, with many clinicians describing this practice as outside their skill set. Additionally, although most clinicians recognized chronic pain as a biopsychosocial phenomenon, they described challenges with effectively managing psychosocial stressors, including difficulty accessing mental or behavioral health services for cancer survivors. CONCLUSION Discovered challenges highlight unmet needs related to cancer survivor-clinician communication about chronic pain and the absence of a chronic pain management home for cancer survivors, including those requiring long-term opioid therapy. Research evaluating routine pain monitoring and accessible, tailored models of multimodal pain care in survivorship may help to address these challenges.
Collapse
Affiliation(s)
- Devon K. Check
- Department of Population Health Sciences, Duke University School of Medicine, Durham, NC
- Duke Cancer Institute, Durham, NC
| | - Katie F. Jones
- Boston College, William F. Connell School of Nursing, Chestnut Hill, MA
| | - Laura J. Fish
- Duke Cancer Institute, Durham, NC
- Department of Family Medicine and Community Health, Duke University School of Medicine, Durham, NC
| | - Michaela A. Dinan
- Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT
- Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, CT
| | - T. Kayla Dunbar
- Doctor of Osteopathic Medicine Program, Philadelphia College of Osteopathic Medicine, Philadelphia, PA
| | | | - Jessica Ma
- Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC
| | - Jessica S. Merlin
- Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Amy O'Regan
- Department of Population Health Sciences, Duke University School of Medicine, Durham, NC
| | - Kevin C. Oeffinger
- Duke Cancer Institute, Durham, NC
- Department of Medicine, Duke University School of Medicine, Durham, NC
| |
Collapse
|
8
|
DiScala S, Uritsky TJ, Brown ME, Abel SM, Humbert NT, Naidu D. Society of Pain and Palliative Care Pharmacists White Paper on the Role of Opioid Stewardship Pharmacists. J Pain Palliat Care Pharmacother 2023; 37:3-15. [PMID: 36519288 DOI: 10.1080/15360288.2022.2149670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Opioid stewardship is one essential function of pain and palliative care pharmacists and a critical need in the United States. In recent years, this country has been plagued by two public health emergencies: an opioid crisis and the COVID-19 pandemic, which has exacerbated the opioid epidemic through its economic and psychosocial toll. To develop an opioid stewardship program, a systematic approach is needed. This will be detailed in part here by the Opioid Stewardship Taskforce of the Society of Pain and Palliative Care Pharmacists (SPPCP), focusing on the role of the pharmacist. Many pain and palliative care pharmacists have made significant contributions to the development and daily operation of such programs while also completing other competing clinical tasks, including direct patient care. To ensure dedicated time and attention to critical opioid stewardship efforts, SPPCP recommends and endorses opioid stewardship models employing a full time, opioid stewardship pharmacist in both the inpatient and outpatient setting. Early research suggests that opioid stewardship pharmacists are pivotal to improving opioid metrics and pain care outcomes. However, further research and development in this area of practice is needed and encouraged.
Collapse
|
9
|
Hamlish T, Pasquinelli M, Gastala N, Huber M, Manst D, Andersen K, Jarrett JB, Neeb C, Tuite J, Maes P, Sung C, Fleurimont J, Feldman L. A team-based approach to effective management of pain and opioid use disorder in patients with cancer: Case report. CURRENT PROBLEMS IN CANCER: CASE REPORTS 2022. [DOI: 10.1016/j.cpccr.2022.100196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
10
|
Kim EJ, Hwang EJ, Yoo YM, Kim KH. Prevention, diagnosis, and treatment of opioid use disorder under the supervision of opioid stewardship programs: it's time to act now. Korean J Pain 2022; 35:361-382. [PMID: 36175336 PMCID: PMC9530691 DOI: 10.3344/kjp.2022.35.4.361] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Revised: 09/15/2022] [Accepted: 09/15/2022] [Indexed: 11/06/2022] Open
Abstract
The third opium war may have already started, not only due to illicit opioid trafficking from the Golden Crescent and Golden Triangle on the international front but also through indiscriminate opioid prescription and opioid diversion at home. Opioid use disorder (OUD), among unintentional injuries, has become one of the top 4 causes of death in the United States (U.S.). An OUD is defined as a problematic pattern of opioid use resulting in clinically significant impairment or distress, consisting of 2 or more of 11 problems within 1 year, as described by the Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition. Observation of aberrant behaviors of OUD is also helpful for overworked clinicians. For the prevention of OUD, the Opioid Risk Tool and the Current Opioid Misuse Measure are appropriate screening tests before and during opioid administration, respectively. Treatment of OUD consists of 3 opioid-based U.S. Food and Drug Administration-approved medications, including methadone, buprenorphine, and naltrexone, and non-opioid-based symptomatic medications for reducing opioid withdrawal syndromes, such as α2 agonists, β-blockers, antidiarrheals, antiemetics, non-steroidal anti-inflammatory drugs, and benzodiazepines. There are at least 6 recommendable guidelines and essential terms related to OUD. Opioid stewardship programs are now critical to promoting appropriate use of opioid medications, improving patient outcomes, and reducing misuse of opioids, influenced by the successful implementation of antimicrobial stewardship programs. Despite the lack of previous motivation, now is the critical time for trying to reduce the risk of OUD.
Collapse
Affiliation(s)
- Eun-Ji Kim
- Department of Pharmacy, Pusan National University Yangsan Hospital, Yangsan, Korea
| | - Eun-Jung Hwang
- Department of Pharmacy, Pusan National University Yangsan Hospital, Yangsan, Korea
| | - Yeong-Min Yoo
- Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Yangsan, Korea
| | - Kyung-Hoon Kim
- Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Yangsan, Korea
| |
Collapse
|
11
|
Kral LA, Bettinger JJ, Vartan CM, Hadlandsmyth K, Kullgren J, Smith MA. A Survey on Opioid Tapering Practices, Policies, and Perspectives by Pain and Palliative Care Pharmacists. J Pain Palliat Care Pharmacother 2022; 36:2-10. [PMID: 35254209 DOI: 10.1080/15360288.2022.2041147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Opioid tapering is an essential clinical tool to utilize for a variety of reasons, including safety and analgesic optimization. The need for individualized regimens reveals a corresponding need for healthcare providers who can actively manage patients throughout the process. Pharmacists have taken on an integral role for achieving success in opioid tapering. This survey was conducted to describe the current opioid tapering practices of pain and palliative care pharmacists. A Qualtrics survey was offered to the Society of Pain and Palliative Care Pharmacist members. The majority (87%) indicated they specialized in pain management. Almost all respondents (98%) reported providing tapering recommendations and 82% reported being involved with patient monitoring throughout the taper. The majority (multiple responses could be chosen) noted that the indication for initiating an opioid taper was due to abuse/misuse (91%), reduced overall efficacy (89%), and adverse drug reactions (78%). The most common follow-up intervals during tapering were weekly (15%), every 2 weeks (22%), and every 4 weeks (44%). This practice-based survey, though small, showed that pharmacists in pain management and palliative care are actively involved in opioid tapering. This survey will hopefully serve as a foundation for continuing research into opioid tapering and the pharmacist's role therein.
Collapse
|
12
|
Kihara A, Shimada K, Tsuneto S. How Do We Taper and Discontinue Opioids in Cancer Patients? Considerations from the Activities of a Palliative Care Team at a University Hospital. Palliat Med Rep 2021; 2:255-259. [PMID: 34927150 PMCID: PMC8675093 DOI: 10.1089/pmr.2020.0105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/23/2021] [Indexed: 11/30/2022] Open
Abstract
Background: The more the cancer treatments progress, the more the needs increase to taper and discontinue opioids in cancer patients. Furthermore, opioid dependence of cancer survivors has become a bigger problem. However, a safe opioid tapering and discontinuation method has not yet been established in cancer patients. Objective: To suggest a safe opioid tapering and discontinuation method in cancer patients. Design: We reviewed opioid type, dose, administration route, administration duration, reason for tapering and discontinuation, and presence/absence of opioid withdrawal symptoms in cancer patients whose opioids needed to be tapered and discontinued. Setting/Subjects: We recruited cancer patients referred to the palliative care team of Kyoto University Hospital-Japan whose opioids were tapered and discontinued. Measurements: Opioid withdrawal symptoms were assessed by two physicians, one nurse, and one pharmacist of palliative care team. Results: Opioids were tapered and discontinued in 25 out of 145 cancer patients (17%). Opioid withdrawal symptoms were observed in 3 of the 25 cases (12%). In withdrawal symptom cases and nonwithdrawal symptom cases, the mean maximum oral morphine-equivalent doses of opioids were 352.0 and 55.7 mg/day, and the mean administration duration of opioid were 82.3 and 28.7 days, respectively. Withdrawal symptoms occurred in patients receiving higher-dose opioids with longer administration duration and their symptoms tended to appear at approximately 10% of the maximum dose. Conclusions: We suggest that withdrawal symptoms may be prevented by using a two-stage method rather than a monotonous tapering method in cancer patients whose higher-dose opioid with longer administration duration needed to be tapered and discontinued.
Collapse
Affiliation(s)
- Ayumi Kihara
- Department of Palliative Medicine, Kyoto Min-iren Asukai Hospital, Kyoto, Japan
| | - Kazuki Shimada
- Department of Palliative Medicine, Kyoto University Hospital, Kyoto, Japan
| | - Satoru Tsuneto
- Department of Palliative Medicine, Kyoto University Hospital, Kyoto, Japan.,Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
13
|
Jones W, Junkins S, Rosielle DA. Tapering Opioids in Patients with Serious Illness: How to Taper #414. J Palliat Med 2021; 24:784-785. [PMID: 33945317 DOI: 10.1089/jpm.2020.0805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Durham DD, Strassels SA, Pinsky PF. Opioid use by cancer status and time since diagnosis among older adults enrolled in the Prostate, Lung, Colorectal, and Ovarian screening trial in the United States. Cancer Med 2021; 10:2175-2187. [PMID: 33638315 PMCID: PMC7957211 DOI: 10.1002/cam4.3810] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2020] [Revised: 02/01/2021] [Accepted: 02/09/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Dosing limits in opioid clinical practice guidelines in the United States are likely misapplied to cancer patients, however, opioid use may be difficult to ascertain as they are largely excluded from opioid use studies. METHODS The primary objective was to determine whether cancer patients were more likely to be chronic opioid users after diagnosis. We described prescription opioid use among U.S. older adult cancer patients during two time periods, within 2 years of diagnosis (short-term) and at least 2 years beyond diagnosis (long-term), compared to those without cancer (controls). Among participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial with linkages to Medicare Part D data during 2011-2015, we used multivariable logistic regression to estimate the association between cancer diagnosis and opioid use outcomes controlling for demographics. The primary outcome of opioid use was measured with the following metrics: Any opioid use, chronic use (90 consecutive days supply of opioid use while allowing for a 7-day gap between refills), high use (average daily morphine equivalent (MME) ≥120 mg for any 90-day period), and total MME dose above 2,000 mg (MME2000 ). RESULTS The short-term cohort included 1,491 cancer patients and 24,930 controls. Any use in the 2-year post-diagnosis period was higher among cancer patients OR 3.3 (95% CI: 3.0-3.7). Chronic use rates were similar by cancer status (4.6% vs. 3.8% for cases and controls, respectively). The long-term cohort included 4,377 cancer patients and 27,545 controls. Rates of any use were similar among cancer patients and controls (63% vs. 59%). CONCLUSIONS Any opioid use was similar among long-term cancer survivors compared to controls, but differed among short-term survivors for any opioid use and marginally for chronic opioid use.
Collapse
Affiliation(s)
- Danielle D Durham
- Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.,Cancer Prevention Fellowship Program, Division of Cancer Prevention, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA
| | - Scott A Strassels
- Center for Surgical Health Assessment Research and Policy, Department of Surgery, The Ohio State University, Columbus, OH, USA
| | - Paul F Pinsky
- Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
| |
Collapse
|
15
|
Jones KF, Fu MR, Merlin JS, Paice JA, Bernacki R, Lee C, Wood LJ. Exploring Factors Associated With Long-Term Opioid Therapy in Cancer Survivors: An Integrative Review. J Pain Symptom Manage 2021; 61:395-415. [PMID: 32822751 DOI: 10.1016/j.jpainsymman.2020.08.015] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 08/06/2020] [Accepted: 08/11/2020] [Indexed: 12/14/2022]
Abstract
CONTEXT The prevalence of chronic pain in cancer survivors is double that of the general U.S. POPULATION Opioids have been the foundation of cancer pain management for decades; however, there is a paucity of literature on long-term opioid therapy (LTOT) in cancer survivors. An understanding of factors related to LTOT use in cancer survivors is needed to address chronic pain and balance opioid harms in the expanding population of cancer survivors. OBJECTIVES To analyze the research of LTOT utilization and factors associated with persistent opioid use in cancer survivors. METHODS A five-stage integrative review process was adapted from Whittemore and Knafl. Data sources searched included Web of Science, PubMed, Embase, Cochrane, and Google Scholar. Quantitative research studies from 2010 to present related to cancer survivors managed on LTOT were included. Editorials, reviews, or abstracts were excluded. RESULTS After reviewing 315 articles, 21 articles were included. We found that there were several definitions of LTOT in the reviewed studies, but the duration of opioid use (i.e., more than three months after completion of curative treatment) was the most common. The reviewed literature describes a relationship between LTOT and important biopsychosocial factors (cancer type, socioeconomic factors, and comorbidities). CONCLUSION The studies in this review shed light on the factors associated with LTOT in cancer survivors. LTOT was common in certain populations of cancer survivors and those with a collection of patient-specific characteristics. This review suggests that there is a critical need for specialized research on chronic cancer pain and opioid safety in cancer survivors.
Collapse
Affiliation(s)
- Katie Fitzgerald Jones
- Boston College, William F. Connell School of Nursing, Chestnut Hill, Massachusetts, USA.
| | - Mei R Fu
- Boston College, William F. Connell School of Nursing, Chestnut Hill, Massachusetts, USA
| | - Jessica S Merlin
- University of Pittsburg School of Medicine, Pittsburg, Pennsylvania, USA
| | - Judith A Paice
- Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
| | | | - Christopher Lee
- Boston College, William F. Connell School of Nursing, Chestnut Hill, Massachusetts, USA
| | - Lisa J Wood
- Boston College, William F. Connell School of Nursing, Chestnut Hill, Massachusetts, USA
| |
Collapse
|
16
|
Haley EM, Stone J, Childers J, Davis A, Ehrman S, Houser MW, Olenik JM, Roche M, Jones CA, Skarf LM. Top Ten Tips Palliative Care Clinicians Should Know About Opioid Use Disorder. J Palliat Med 2020; 23:1250-1256. [PMID: 32716738 DOI: 10.1089/jpm.2020.0409] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Since the prevalence of substance use disorders, and opioid use disorder (OUD) specifically, remains high and represents a public health crisis, it is critical that palliative care (PC) providers have a broad understanding of this class of chronic, yet treatable, diseases. Conceptualizing stigma associated with OUD, treatment modalities available, and educational opportunities are key factors in providing patient-centered care. A solid foundation of knowledge about OUD in the setting of serious illness is also crucial as PC providers often recommend or prescribe opioids for symptom management in patients who also have OUD. Furthermore, the PC interdisciplinary team is particularly well poised to care for patients suffering from OUD due to the inherently holistic approach already present in the specialty of PC. This article offers PC teams a framework for understanding the diagnosis and treatment of OUD, methods for performing risk stratification and monitoring, and an overview of opportunities to enhance our care of PC patients with OUD.
Collapse
Affiliation(s)
- Erin M Haley
- Palliative Care Service, Department of Medicine, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
| | - Jordan Stone
- Section of Palliative Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Julie Childers
- Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Amy Davis
- Drexel University School of Medicine, Philadelphia, Pennsylvania, USA
| | - Sarah Ehrman
- Division of Palliative Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Mackenzie W Houser
- Palliative Care Team, Main Line Health, Newtown Square, Pennsylvania, USA
| | - Jennifer M Olenik
- Section of Palliative Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Meaghan Roche
- Division of Renal Electrolyte and Hypertension, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Christopher A Jones
- Section of Palliative Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Lara M Skarf
- Division of Geriatrics and Palliative Care, Department of Medicine, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA
| |
Collapse
|